Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,254.00
(
0.62%
)
US TECH 100
27,012.80
(
1.14%
)
Dow Jones
49,656.66
(
0.01%
)
Brent Oil
107.37
(
-2.71%
)
Bitcoin
78,503.02
(
2.85%
)
News Focus
News Focus
Post# of 130347
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

RNsidersbuying

Send PM Follow Ignore
Followers 48
Posts 4771
Boards Moderated 0
Alias Born 07/26/2010

RNsidersbuying

Re: RNsidersbuying post# 80744

Wednesday, 12/09/2020 4:17:57 PM

Wednesday, December 09, 2020 4:17:57 PM

Post# of 130347
NBIO .05 - On December 7, 2020, the Company received a letter from the Federal Drug Administration (FDA) releasing the partial hold on the Company’s antibody Pritumumab. The release clears the Company to begin phase 1 clinical trials with its drug substance product.

Based on the approval by the FDA, the Company anticipates clinical trials to begin the first week in January, 2021.

https://ih.advfn.com/stock-market/USOTC/nascent-biotech-qb-NBIO/stock-news/83866997/current-report-filing-8-k
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today